Literature DB >> 16012855

Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil.

Amadu E Juliana1, Filomena C B Abbad.   

Abstract

UNLABELLED: We present the case of a full term neonate with severe persistent pulmonary hypertension of the newborn (PPHN) after birth asphyxia cared for at the St. Elizabeth Hospital in Curacao, Netherlands Antilles. Although the child was ventilated with high pressures and was given high doses of cardiovascular pressors, the arterial oxygen levels remained low with an alveolar-arterial O2 gradient of 651 mmHg. As a last resort, sildenafil (1.5 mg/kg) was given via a nasogastric tube. This resulted in an immediate and sustained elevation of arterial oxygenation and subsequent complete recovery. After administration of sildenafil there was a transient hypotension which was corrected by a single bolus of saline.
CONCLUSION: We discuss the current treatment modalities of persistent pulmonary hypertension of the newborn and the potential use of phosphodiesterase 5 inhibitors such as sildenafil in a situation where the standard of practice with inhaled nitric oxide and extracorporeal membrane oxygenation is not available.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012855     DOI: 10.1007/s00431-005-1724-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes.

Authors:  M C Walsh-Sukys; J E Tyson; L L Wright; C R Bauer; S B Korones; D K Stevenson; J Verter; B J Stoll; J A Lemons; L A Papile; S Shankaran; E F Donovan; W Oh; R A Ehrenkranz; A A Fanaroff
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

2.  American Academy of Pediatrics. Committee on Fetus and Newborn. Use of inhaled nitric oxide.

Authors: 
Journal:  Pediatrics       Date:  2000-08       Impact factor: 7.124

Review 3.  Chemotherapeutic potential of phosphodiesterase inhibitors.

Authors:  M J Perry; G A Higgs
Journal:  Curr Opin Chem Biol       Date:  1998-08       Impact factor: 8.822

4.  Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group.

Authors:  J D Roberts; J R Fineman; F C Morin; P W Shaul; S Rimar; M D Schreiber; R A Polin; M S Zwass; M M Zayek; I Gross; M A Heymann; W M Zapol
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

5.  Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure.

Authors: 
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

6.  Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group.

Authors:  D Davidson; E S Barefield; J Kattwinkel; G Dudell; M Damask; R Straube; J Rhines; C T Chang
Journal:  Pediatrics       Date:  1998-03       Impact factor: 7.124

7.  Selective pulmonary vasodilation induced by aerosolized zaprinast.

Authors:  F Ichinose; C Adrie; W E Hurford; K D Bloch; W M Zapol
Journal:  Anesthesiology       Date:  1998-02       Impact factor: 7.892

8.  Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group.

Authors:  R H Clark; T J Kueser; M W Walker; W M Southgate; J L Huckaby; J A Perez; B J Roy; M Keszler; J P Kinsella
Journal:  N Engl J Med       Date:  2000-02-17       Impact factor: 91.245

9.  Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension.

Authors:  Lara S Shekerdemian; Hanne B Ravn; Daniel J Penny
Journal:  Am J Respir Crit Care Med       Date:  2002-04-15       Impact factor: 21.405

10.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.

Authors:  R M Wallis; J D Corbin; S H Francis; P Ellis
Journal:  Am J Cardiol       Date:  1999-03-04       Impact factor: 2.778

View more
  13 in total

Review 1.  Sildenafil for pulmonary hypertension in neonates.

Authors:  Lauren E Kelly; Arne Ohlsson; Prakeshkumar S Shah
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

Review 2.  Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension.

Authors:  Leah Leibovitch; Ilan Matok; Gideon Paret
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

Review 4.  Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.

Authors:  Danielle Harake; Vivian I Franco; Jacqueline M Henkel; Tracie L Miller; Steven E Lipshultz
Journal:  Future Cardiol       Date:  2012-07

5.  Effect of a phosphodiesterase 5 inhibitor on pulmonary and cerebral arteries of newborn piglets with chronic hypoxia-induced pulmonary hypertension.

Authors:  Candice D Fike; Mark Kaplowitz; Yongmei Zhang; Mark Dantuma; Jane A Madden
Journal:  Neonatology       Date:  2011-07-26       Impact factor: 4.035

6.  Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension.

Authors:  Hugo Juárez Olguín; Hector Osnaya Martínez; Carmen Flores Pérez; Blanca Ramírez Mendiola; Liliana Rivera Espinosa; Juan Luis Chávez Pacheco; Janett Flores Pérez; Ignacio Mora Magaña
Journal:  World J Pediatr       Date:  2017-08-08       Impact factor: 2.764

7.  Initial Experience with Sildenafil, Bosentan, and Nitric Oxide for Pediatric Cardiomyopathy Patients with Elevated Pulmonary Vascular Resistance before and after Orthotopic Heart Transplantation.

Authors:  Babak Daftari; Juan Carlos Alejos; Gregory Perens
Journal:  J Transplant       Date:  2010-03-10

Review 8.  Sildenafil for the treatment of pulmonary hypertension in pediatric patients.

Authors:  Alice J Huddleston; Chad A Knoderer; Jennifer L Morris; Eric S Ebenroth
Journal:  Pediatr Cardiol       Date:  2009-08-25       Impact factor: 1.655

Review 9.  Is sildenafil an effective therapy in the management of persistent pulmonary hypertension?

Authors:  Hakam Yaseen; Maha Darwich; Hossam Hamdy
Journal:  J Clin Neonatol       Date:  2012-10

10.  Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.

Authors:  Yvonne P de Visser; Frans J Walther; El Houari Laghmani; Hester Boersma; Arnoud van der Laarse; Gerry Tm Wagenaar
Journal:  Respir Res       Date:  2009-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.